Oncology

Aragen offers a diverse range of oncology disease models and services to customize study designs for specific projects. These include human xenograft tumor models as well as the more complex sub-renal capsule, patient-derived xenograft (PDX), and syngeneic tumor models. Xenograft models of human cancer play an important role in screening and evaluation of NCEs and NBEs as potential anticancer agents. Aragen scientists have developed and validated several xenograft models in Ncr Nu/Nu, NOD-SCID and SCID-Beige mice. We can customize and utilize any human cell line of interest to conduct in vivo proof-of concept studies for client NCEs and NBEs. Syngeneic models are tumor models whose genetic background is similar, if not identical to the host animal. As they retain an intact immune system, syngeneic models can be particularly pertinent for studies of immunologically-based targeted therapies that are either standalone or combinations. PK/PD correlations can be established by relating plasma and tumor exposure to tumor volume and weight, as well as to a panel of genomic, proteomic and metabolomic biomarkers.

Validated Xenograft/ Syngeneic Models

Human Tumor Xenograft 

Syngeneic Tumor Models

Additional Models

• Lung metastasis model
• Orthotopic models of breast, kidney
• Subrenal capsule assay
• Vaccine model

Other Oncology Support

• In Vivo Bioluminescent Imaging
• 70+ cancer cell lines stored in-house to validate new models
• Pharmacokinetics and bioavailability of various test materials in tumour bearing mice
• Target engagement of compound in tumour tissue and PK/PD correlation
• MTD studies in immunocompromised mice